GlassScriptPhysician profile
Whitney T Krawczyk
NPI 1477060390
$1,324.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $515 · 2022: $810.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.91 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $192.58 | 2021-2022 | |
| Alkermes, INC. | $86.83 | 2021-2022 | |
| Bausch Health US, LLC | $76.70 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $63.60 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $55.66 | 2021-2022 | |
| Axsome Therapeutics, INC. | $55.56 | 2022 | |
| Corium, LLC | $39.17 | 2022 | |
| Lundbeck LLC | $30.14 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $22.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.40 | 2022 | |
| Neurocrine Biosciences, INC. | $18.20 | 2021 | |
| Redhill Biopharma INC. | $15.52 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Krawczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.